DexCom (DXCM) Competitors

$58.57 -2.57 (-4.20%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$58.89 +0.32 (+0.55%)

As of 05/13/2026 07:56 PM Eastern

DXCM vs. HQY, PODD, ABT, AMN, and ITGR

Should you buy DexCom stock or one of its competitors? MarketBeat compares DexCom with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with DexCom include HealthEquity (HQY), Insulet (PODD), Abbott Laboratories (ABT), AMN Healthcare Services (AMN), and Integer (ITGR). These companies are all part of the "medical" sector.

How does DexCom compare to HealthEquity?

DexCom (NASDAQ:DXCM) and HealthEquity (NASDAQ:HQY) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.

DexCom has a net margin of 19.31% compared to HealthEquity's net margin of 16.39%. DexCom's return on equity of 33.33% beat HealthEquity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DexCom	19.31%	33.33%	13.19%
HealthEquity	16.39%	13.86%	8.67%

DexCom has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market. Comparatively, HealthEquity has a beta of 0.19, indicating that its share price is 81% less volatile than the broader market.

97.8% of DexCom shares are owned by institutional investors. Comparatively, 99.6% of HealthEquity shares are owned by institutional investors. 0.3% of DexCom shares are owned by insiders. Comparatively, 1.5% of HealthEquity shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, DexCom had 15 more articles in the media than HealthEquity. MarketBeat recorded 22 mentions for DexCom and 7 mentions for HealthEquity. HealthEquity's average media sentiment score of 1.35 beat DexCom's score of 1.16 indicating that HealthEquity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DexCom	13 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
HealthEquity	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

DexCom presently has a consensus price target of $83.22, suggesting a potential upside of 42.08%. HealthEquity has a consensus price target of $111.79, suggesting a potential upside of 36.03%. Given DexCom's stronger consensus rating and higher possible upside, equities research analysts clearly believe DexCom is more favorable than HealthEquity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DexCom	1 Sell rating(s)	3 Hold rating(s)	18 Buy rating(s)	3 Strong Buy rating(s)	2.92
HealthEquity	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

DexCom has higher revenue and earnings than HealthEquity. DexCom is trading at a lower price-to-earnings ratio than HealthEquity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DexCom	$4.66B	4.85	$836.30M	$2.34	25.03
HealthEquity	$1.31B	5.29	$215.20M	$2.46	33.41

Summary

DexCom beats HealthEquity on 11 of the 17 factors compared between the two stocks.

How does DexCom compare to Insulet?

DexCom (NASDAQ:DXCM) and Insulet (NASDAQ:PODD) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.

DexCom presently has a consensus price target of $83.22, suggesting a potential upside of 42.08%. Insulet has a consensus price target of $257.09, suggesting a potential upside of 72.73%. Given Insulet's higher possible upside, analysts clearly believe Insulet is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DexCom	1 Sell rating(s)	3 Hold rating(s)	18 Buy rating(s)	3 Strong Buy rating(s)	2.92
Insulet	1 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.72

DexCom has higher revenue and earnings than Insulet. DexCom is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DexCom	$4.66B	4.85	$836.30M	$2.34	25.03
Insulet	$2.71B	3.81	$247.10M	$4.30	34.61

DexCom has a net margin of 19.31% compared to Insulet's net margin of 10.44%. DexCom's return on equity of 33.33% beat Insulet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DexCom	19.31%	33.33%	13.19%
Insulet	10.44%	26.87%	12.01%

DexCom has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market. Comparatively, Insulet has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market.

In the previous week, Insulet had 29 more articles in the media than DexCom. MarketBeat recorded 51 mentions for Insulet and 22 mentions for DexCom. DexCom's average media sentiment score of 1.16 beat Insulet's score of 0.04 indicating that DexCom is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DexCom	13 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
Insulet	6 Very Positive mention(s)	9 Positive mention(s)	4 Neutral mention(s)	19 Negative mention(s)	0 Very Negative mention(s)	Neutral

97.8% of DexCom shares are owned by institutional investors. 0.3% of DexCom shares are owned by insiders. Comparatively, 0.4% of Insulet shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

DexCom beats Insulet on 11 of the 17 factors compared between the two stocks.

How does DexCom compare to Abbott Laboratories?

Abbott Laboratories (NYSE:ABT) and DexCom (NASDAQ:DXCM) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, dividends and earnings.

Abbott Laboratories currently has a consensus price target of $119.43, suggesting a potential upside of 42.47%. DexCom has a consensus price target of $83.22, suggesting a potential upside of 42.08%. Given Abbott Laboratories' higher probable upside, analysts clearly believe Abbott Laboratories is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abbott Laboratories	0 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.88
DexCom	1 Sell rating(s)	3 Hold rating(s)	18 Buy rating(s)	3 Strong Buy rating(s)	2.92

Abbott Laboratories has higher revenue and earnings than DexCom. Abbott Laboratories is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abbott Laboratories	$44.33B	3.29	$6.52B	$3.57	23.48
DexCom	$4.66B	4.85	$836.30M	$2.34	25.03

DexCom has a net margin of 19.31% compared to Abbott Laboratories' net margin of 13.90%. DexCom's return on equity of 33.33% beat Abbott Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abbott Laboratories	13.90%	17.62%	10.01%
DexCom	19.31%	33.33%	13.19%

Abbott Laboratories has a beta of 0.65, suggesting that its stock price is 35% less volatile than the broader market. Comparatively, DexCom has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market.

In the previous week, Abbott Laboratories had 15 more articles in the media than DexCom. MarketBeat recorded 37 mentions for Abbott Laboratories and 22 mentions for DexCom. DexCom's average media sentiment score of 1.16 beat Abbott Laboratories' score of 0.99 indicating that DexCom is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abbott Laboratories	20 Very Positive mention(s)	6 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive
DexCom	13 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

75.2% of Abbott Laboratories shares are held by institutional investors. Comparatively, 97.8% of DexCom shares are held by institutional investors. 0.5% of Abbott Laboratories shares are held by company insiders. Comparatively, 0.3% of DexCom shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

DexCom beats Abbott Laboratories on 10 of the 17 factors compared between the two stocks.

How does DexCom compare to AMN Healthcare Services?

AMN Healthcare Services (NYSE:AMN) and DexCom (NASDAQ:DXCM) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, dividends and earnings.

DexCom has a net margin of 19.31% compared to AMN Healthcare Services' net margin of -0.95%. DexCom's return on equity of 33.33% beat AMN Healthcare Services' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AMN Healthcare Services	-0.95%	18.01%	5.19%
DexCom	19.31%	33.33%	13.19%

99.2% of AMN Healthcare Services shares are held by institutional investors. Comparatively, 97.8% of DexCom shares are held by institutional investors. 1.1% of AMN Healthcare Services shares are held by company insiders. Comparatively, 0.3% of DexCom shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

AMN Healthcare Services has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market. Comparatively, DexCom has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market.

DexCom has higher revenue and earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AMN Healthcare Services	$2.73B	0.44	-$95.70M	-$0.87	N/A
DexCom	$4.66B	4.85	$836.30M	$2.34	25.03

In the previous week, DexCom had 2 more articles in the media than AMN Healthcare Services. MarketBeat recorded 22 mentions for DexCom and 20 mentions for AMN Healthcare Services. DexCom's average media sentiment score of 1.16 beat AMN Healthcare Services' score of 0.66 indicating that DexCom is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AMN Healthcare Services	4 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
DexCom	13 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

AMN Healthcare Services currently has a consensus price target of $25.29, suggesting a potential downside of 17.97%. DexCom has a consensus price target of $83.22, suggesting a potential upside of 42.08%. Given DexCom's stronger consensus rating and higher probable upside, analysts clearly believe DexCom is more favorable than AMN Healthcare Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AMN Healthcare Services	2 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.44
DexCom	1 Sell rating(s)	3 Hold rating(s)	18 Buy rating(s)	3 Strong Buy rating(s)	2.92

Summary

DexCom beats AMN Healthcare Services on 15 of the 17 factors compared between the two stocks.

How does DexCom compare to Integer?

Integer (NYSE:ITGR) and DexCom (NASDAQ:DXCM) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

Integer currently has a consensus price target of $98.29, indicating a potential upside of 10.00%. DexCom has a consensus price target of $83.22, indicating a potential upside of 42.08%. Given DexCom's stronger consensus rating and higher probable upside, analysts clearly believe DexCom is more favorable than Integer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integer	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
DexCom	1 Sell rating(s)	3 Hold rating(s)	18 Buy rating(s)	3 Strong Buy rating(s)	2.92

DexCom has a net margin of 19.31% compared to Integer's net margin of 7.64%. DexCom's return on equity of 33.33% beat Integer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Integer	7.64%	12.83%	6.51%
DexCom	19.31%	33.33%	13.19%

Integer has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market. Comparatively, DexCom has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market.

99.3% of Integer shares are owned by institutional investors. Comparatively, 97.8% of DexCom shares are owned by institutional investors. 1.1% of Integer shares are owned by company insiders. Comparatively, 0.3% of DexCom shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

DexCom has higher revenue and earnings than Integer. Integer is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integer	$1.85B	1.64	$102.81M	$4.01	22.28
DexCom	$4.66B	4.85	$836.30M	$2.34	25.03

In the previous week, DexCom had 11 more articles in the media than Integer. MarketBeat recorded 22 mentions for DexCom and 11 mentions for Integer. DexCom's average media sentiment score of 1.16 beat Integer's score of 0.67 indicating that DexCom is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Integer	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DexCom	13 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

DexCom beats Integer on 14 of the 17 factors compared between the two stocks.

Get DexCom News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DXCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DXCM vs. The Competition

Export

Metric	DexCom	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$23.59B	$6.90B	$6.30B	$12.20B
Dividend Yield	N/A	1.72%	2.79%	5.30%
P/E Ratio	25.03	49.93	21.23	25.65
Price / Sales	4.85	66.56	558.10	79.80
Price / Cash	22.08	24.21	42.94	55.34
Price / Book	7.65	6.49	9.70	6.66
Net Income	$836.30M	$158.34M	$3.55B	$333.63M
7 Day Performance	-3.84%	-1.83%	-0.55%	-0.11%
1 Month Performance	-6.96%	-1.10%	1.19%	3.94%
1 Year Performance	-32.30%	-2.35%	41.20%	36.07%

DexCom Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DXCM DexCom	4.7096 of 5 stars	$58.57 -4.2%	$83.22 +42.1%	-30.4%	$23.59B	$4.66B	25.03	11,000	Positive News Analyst Downgrade
HQY HealthEquity	4.1896 of 5 stars	$81.65 -3.8%	$111.79 +36.9%	-15.3%	$6.90B	$1.31B	33.19	2,814	Positive News
PODD Insulet	4.5995 of 5 stars	$154.17 +0.0%	$257.09 +66.8%	-52.7%	$10.68B	$2.71B	35.85	5,400	Analyst Forecast
ABT Abbott Laboratories	4.9528 of 5 stars	$82.58 -2.1%	$119.43 +44.6%	-35.0%	$143.84B	$44.33B	23.13	115,000	Trending News
AMN AMN Healthcare Services	1.7479 of 5 stars	$30.43 +5.0%	$23.50 -22.8%	+41.3%	$1.18B	$2.73B	N/A	2,664	News Coverage Earnings Report Analyst Forecast High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DXCM) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DexCom (DXCM) Competitors